EMA Authorised: Multaq (dronedarone) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorised Multaq (dronedarone) for the treatment of atrial fibrillation under the Sanofi Winthrop Industrie marketing authorization. The decision confirms …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Multaq (dronedarone)

Snippet

Status: Authorised. Therapeutic area: Atrial Fibrillation. MAH: Sanofi Winthrop Industrie. Decision date: 28/10/2025